- Presentations to be webcast on www.exelixis.com -
Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion
– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – ...
– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal...
– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy –
– Presentation to be webcast on www.exelixis.com –
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.